新生儿阿片类戒断综合征（NOWS）治疗的禁欲评分算法。
Abstinence scoring algorithms for treatment of neonatal opioid withdrawal syndrome (NOWS).
机构信息
Department of Neurology, University of California, Irvine, CA, USA.
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
出版信息
J Perinatol. 2024 Aug;44(8):1132-1136. doi: 10.1038/s41372-024-01895-6. Epub 2024 Feb 16.
OBJECTIVE
Chervoneva et al. (2020) developed an abbreviated score (sMNAS-9) derived from full modified Finnegan MOTHER NAS scale (MNAS) for evaluating severity of NOWS. We sought to develop NOWS treatment algorithms for clinical decision rules based on scores utilizing the shorter sMNAS.
STUDY DESIGN
This was a retrospective study of 373 infants with NOWS scored with MNAS and treated with morphine between 2007 and 2016. The infants were randomly split into training/test sets. The training set was used to derive optimized cutoff values for sMNAS-9 scores. The independent set evaluated the sMNAS-9 clinical decision rules based on full MNAS in NOWS morphine and buprenorphine treatment algorithms.
RESULT
Clinical decision rules based on sMNAS-9 yielded sensitivities of 88% or higher and specificities of 85% or higher for predicting the respective rules based on full MNAS.
CONCLUSION
The sMNAS-9 scoring instrument is expected to yield similar clinical decisions in treatment of NOWS.
目的
Chervoneva 等人（2020 年）从改良后的 Finnegan 母亲新生儿行为评估量表（MNAS）中开发了一种简化评分（sMNAS-9），用于评估新生儿戒断综合征（NOWS）的严重程度。我们试图基于该评分制定基于评分的临床决策规则，以开发用于吗啡治疗的 NOWS 治疗算法。
研究设计
这是一项回顾性研究，纳入了 2007 年至 2016 年间接受 MNAS 评分和吗啡治疗的 373 例 NOWS 婴儿。这些婴儿被随机分为训练/测试集。训练集用于得出 sMNAS-9 评分的最佳截断值。独立集评估了基于完整 MNAS 的 sMNAS-9 临床决策规则，用于吗啡和丁丙诺啡治疗 NOWS 的算法。
结果
基于 sMNAS-9 的临床决策规则在预测相应的基于完整 MNAS 的规则时，灵敏度均在 88%或更高，特异性均在 85%或更高。
结论
sMNAS-9 评分工具有望在治疗 NOWS 方面产生相似的临床决策。
Zotero 插件